Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S, Naumann A, Paulsen F, Zips D, von Hehn U, Ritz R, Tatagiba MS, Tabatabai G. Skardelly M, et al. Among authors: borchers c. Oncologist. 2017 May;22(5):570-575. doi: 10.1634/theoncologist.2016-0347. Epub 2017 Mar 30. Oncologist. 2017. PMID: 28360216 Free PMC article.
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U. Kebir S, et al. Among authors: borchers c. J Neurooncol. 2019 Sep;144(3):501-509. doi: 10.1007/s11060-019-03246-4. Epub 2019 Jul 19. J Neurooncol. 2019. PMID: 31325144 Clinical Trial.
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Reijneveld JC, Taphoorn MJB, Coens C, Bromberg JEC, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG. Reijneveld JC, et al. Among authors: borchers c. Lancet Oncol. 2016 Nov;17(11):1533-1542. doi: 10.1016/S1470-2045(16)30305-9. Epub 2016 Sep 27. Lancet Oncol. 2016. PMID: 27686943 Clinical Trial.
Digitalomics - digital transformation leading to omics insights.
Balasubramaniam NK, Penberthy S, Fenyo D, Viessmann N, Russmann C, Borchers CH. Balasubramaniam NK, et al. Among authors: borchers ch. Expert Rev Proteomics. 2024 Sep-Oct;21(9-10):337-344. doi: 10.1080/14789450.2024.2413107. Epub 2024 Oct 11. Expert Rev Proteomics. 2024. PMID: 39364775 Review.
Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma.
Méant A, Moussa O, Lebeau B, Gonçalves C, Richard VR, Cai F, Prabhu SA, Langke M, Guettler EM, Su J, Gagnon N, Zahedi RP, Borchers CH, Miller WH Jr, Del Rincón SV, Witcher M. Méant A, et al. Among authors: borchers ch. J Invest Dermatol. 2024 Oct 1:S0022-202X(24)02160-2. doi: 10.1016/j.jid.2024.07.037. Online ahead of print. J Invest Dermatol. 2024. PMID: 39357785 Free article. No abstract available.
Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasis.
Preston SEJ, Dahabieh MS, Flores González RE, Gonçalves C, Richard VR, Leibovitch M, Dakin E, Papadopoulos T, Lopez Naranjo C, McCallum PA, Huang F, Gagnon N, Perrino S, Zahedi RP, Borchers CH, Jones RG, Brodt P, Miller WH Jr, Del Rincón SV. Preston SEJ, et al. Among authors: borchers ch. Sci Adv. 2024 Sep 13;10(37):eadi7673. doi: 10.1126/sciadv.adi7673. Epub 2024 Sep 13. Sci Adv. 2024. PMID: 39270021 Free PMC article.
432 results